AJR Am J Roentgenol. 2016 Jan;206(1):162-72. doi: 10.2214/AJR.15.14968. Epub 2015 Oct 22.
Rosenkrantz AB1, Friedman K1, Chandarana H1, Melsaether A1, Moy L1, Ding YS1, Jhaveri K2,3, Beltran L1, Jain R1.
OBJECTIVE: This review article explores recent advancements in PET/MRI for clinical oncologic imaging.
CONCLUSION: Radiologists should understand the technical considerations that have made PET/MRI feasible within clinical workflows, the role of PET tracers for imaging various molecular targets in oncology, and advantages of hybrid PET/MRI compared with PET/CT. To facilitate this understanding, we discuss clinical examples (including gliomas, breast cancer, bone metastases, prostate cancer, bladder cancer, gynecologic malignancy, and lymphoma) as well as future directions, challenges, and areas for continued technical optimization for PET/MRI.